Carvykti is developed by Johnson & Johnson.

What development phase is Carvykti in?

Carvykti is FDA-approved (marketed).

What is the generic name of Carvykti?

ciltacabtagene autoleucel is the generic (nonproprietary) name of Carvykti.

Last reviewed 2026-04-20 · How we verify

Carvykti (ciltacabtagene autoleucel)

Johnson & Johnson · FDA-approved active

At a glance

Generic name	ciltacabtagene autoleucel
Sponsor	Johnson & Johnson
Therapeutic area	Oncology
Phase	FDA-approved
Annual revenue	1100

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carvykti CI brief — competitive landscape report
Carvykti updates RSS · CI watch RSS
Johnson & Johnson portfolio CI